Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Pharmaceuticals

R&D

Medical needs are always diversifying – here's how Meiji is responding.

Year in Review

Year ended March 2022

Key Figures

Net Sales
¥1,013.0billion
15.0%
Operating Income
¥92.9billion
12.4%
Operating Income Ratio
9.2%
0.3percentage points
ROE
13.5%
2.4percentage points
Capital Expenditures
¥93.1billion
R&D Expenses
¥33.4billion

Breakdown by Segment

  • Food
  • Pharmaceuticals

Net Sales

Operating Income

Business Performance Analysis

Food
Net Sales
¥826.0billion
17.4%
Operating Income
¥75.9billion
13.1%
Income Analysis(Billions of yen)
Pharmaceuticals
Net Sales
¥187.9billion
2.9%
Operating Income
¥18.6billion
2.3%
Income Analysis(Billions of yen)

Capital Expenditures

  • Food
  • Pharmaceuticals

Food

¥75.9billion

Pharmaceuticals

¥17.0billion

Cash Dividends per Share / Dividend Payout Ratio

  • Cash Dividends per Share
  • Dividend Payout Ratio

Future Prospects

This is our Medium-term Business Plan,
FYE 3/2022 through FYE 3/2024.



  • Net sales
  • Operating income
  • Operating income ratio
  • ROE
  • FYE 3/2021
    Results
  • ¥1,007.1 billion
  • ¥106.0 billion
  • 10.5%
  • 11.1%
  • FYE 3/2022
    Results
  • ¥1,013.0 billion
  • ¥92.9 billion
  • 9.2%
  • 13.5%
  • FYE 3/2024
    Targets *
  • ¥1,080.0 billion
  • ¥120.0 billion
  • 11.1%
  • 11.0%

* as of May 18, 2021

*The Accounting Standard for Revenue Recognition is applied from FYE 3/2022. As such, the above figures are calculted based on assumption of accounting treatment changes related to revenue recognition.